Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Johnson & Johnson
(NY:
JNJ
)
161.99
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Johnson & Johnson
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
3 Retirement All-Stars for Steady Growth and Income
July 01, 2024
Retirement stocks lead the pack with steady dividends and strong growth potential. Invest smartly for a worry-free retirement.
Via
InvestorPlace
Topics
Retirement
Exposures
Pension
3 Dividend Stocks Yielding Over 3% With Multi-Decade Payout Growth Streaks
July 01, 2024
Explore three high-yield dividend stocks that not only offer yields of 3% or more but also boast multiple decades of payout growth.
Via
InvestorPlace
Assessing Johnson & Johnson's Performance Against Competitors In Pharmaceuticals Industry
July 01, 2024
Via
Benzinga
Judge Blocks Cancer Victims' Attempt To Stop Johnson & Johnson Bankruptcy Plan
July 01, 2024
A federal judge rejected a bid by cancer victims to block Johnson & Johnson from pursuing a $6.48 billion bankruptcy settlement for talc-related lawsuits, stating potential harm was "strictly...
Via
Benzinga
Topics
Bankruptcy
Lawsuit
Exposures
Financial
Legal
3 Magnificent Stocks Retirees Can Buy and Hold Forever
July 01, 2024
These stocks could be ideal for investors in their golden years.
Via
The Motley Fool
Boing! 7 Undervalued Stocks That Could Surprise the Skeptics.
July 01, 2024
The market previously supported a higher multiple for these undervalued stocks, making them attractive contrarian targets.
Via
InvestorPlace
Exploring NYSE:JNJ's dividend characteristics.
June 28, 2024
Analyzing JOHNSON & JOHNSON (NYSE:JNJ)'s Dividend Potential.
Via
Chartmill
Johnson & Johnson's Options: A Look at What the Big Money is Thinking
June 24, 2024
Via
Benzinga
Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn’t Discovered Yet
June 30, 2024
Undiscovered small-cap stocks hold the greatest potential for creating investor wealth as they can take off at a moment's notice.
Via
InvestorPlace
2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off
June 30, 2024
Income-seeking investors can find plenty of opportunities in any market environment.
Via
The Motley Fool
4 Cheap Stocks to Buy in July
June 29, 2024
All four of these stocks are trading at very intriguing valuations.
Via
The Motley Fool
10 Blue-Chip Dividend Growth Stocks With 3% Yields And Safe Dividends
June 28, 2024
A look at 10 blue-chip dividend growth stocks with yields above 3%, the opportunity for those yields to continue growing in the future, and where we can be very certain that the dividend is safe.
Via
Talk Markets
Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600
June 28, 2024
Protagonist Therapeutics will join the SmallCap 600 on Wednesday.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
June 28, 2024
Via
Benzinga
Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue
June 27, 2024
From
Beasley Allen
Via
Business Wire
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
June 27, 2024
The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy.
Via
Benzinga
Exposures
Product Safety
2 Incredible Dividend Growth Stocks to Buy Right Now
June 27, 2024
These two dividend growth stocks can level up your portfolio.
Via
The Motley Fool
Is Johnson & Johnson Stock a Buy?
June 27, 2024
Johnson & Johnson's business is growing at a decent rate, but there's still a fair bit of risk surrounding the company.
Via
The Motley Fool
The 3 Smartest Dow Stocks to Buy With $1000 Right Now
June 26, 2024
Explore why these three well-known Dow stocks to buy are well worth your next $1,000 investment to grow your portfolio.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
June 26, 2024
Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners.
Via
Benzinga
Is Johnson & Johnson the Best Dividend Stock for You?
June 25, 2024
J&J is the textbook blue chip stock -- but it's not for everyone.
Via
The Motley Fool
Supreme Court Backs Pharmaceutical Giants in Iraq Terrorism Funding Case
June 24, 2024
The U.S. Supreme Court supports pharmaceutical companies, led by AstraZeneca, in a lawsuit accusing them of funding terrorism in Iraq, dismissing a lower court's ruling and sending the case back for...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
The Top 3 Sectors Poised For Growth This Summer
June 24, 2024
Communications, technology, and healthcare are the three hottest sectors for growth, but not all stocks will rise with the tides.
Via
MarketBeat
Topics
ETFs
3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold
June 22, 2024
The pharmaceutical industry giants offer reliable profit growth and above-average dividend yields.
Via
The Motley Fool
2 Top Stocks to Buy Now for Years of Passive Income
June 22, 2024
These tried-and-true businesses could be wise additions to your portfolio.
Via
The Motley Fool
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
June 21, 2024
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments.
Via
Benzinga
Johnson & Johnson Completes Acquisition of Proteologix, Inc.
June 21, 2024
From
Johnson & Johnson
Via
Business Wire
Johnson & Johnson Faces New Lawsuit(s) Related To Its Talc Products
June 20, 2024
Johnson & Johnson faces a new class action lawsuit seeking damages and medical monitoring for cancer risk from talc products.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme
June 20, 2024
From
Beasley Allen
Via
Business Wire
Johnson & Johnson's Arthritis Drug Shows Potential In Crohn's Disease
June 20, 2024
Johnson & Johnson announced that their Phase 3 GRAVITI study of Tremfya (guselkumab) SC therapy for Crohn's disease met all primary and secondary endpoints.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.